An improved process for preparation of dexlansoprazole

Inventor(s)

Anonymous

Abstract

Dexlansoprazole (R)-(+)-([3-methyl-4-(2,2,2- trifluoroethoxy) pyridine-2yl]methylsulfinyl)- 1H-benzo [d]imidazole is a proton pump inhibitor developed by Takeda pharmaceuticals. Dexlansoprazole is available as Dexilant in the market with 30 mg and 60 mg dosage forms for oral administration. First time United States Food and Drug Administration (USFDA) is approved for the treatment of erosive esophagitis and non-erosive gastroesophageal reflux disease (GERD or GORD)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Anonymous, "An improved process for preparation of dexlansoprazole", Technical Disclosure Commons, (August 12, 2025)
https://www.tdcommons.org/dpubs_series/8458